Comera Life Sciences Holdings (Comera Life Sciences Holdings) GF Score : 0/100 (As of Jun. 03, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Comera Life Sciences Holdings GF Score?

Comera Life Sciences Holdings has the GF Score of 0, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 0/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Comera Life Sciences Holdings might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Comera Life Sciences Holdings (OTCPK:CMRA) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Comera Life Sciences Holdings GF Score Related Terms

Thank you for viewing the detailed overview of Comera Life Sciences Holdings's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Comera Life Sciences Holdings (Comera Life Sciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Comera Life Sciences Holdings Inc (OTCPK:CMRA) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

12 Gill Street, Suite 4650, Woburn, MA, USA, 01801

Website

https://www.comeralifesciences.com

Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.

Executives

Michael Gerard Campbell	officer: Chief Financial Officer	C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Charles Cherington	10 percent owner	ONE BOW STREET, CAMBRIDGE MA 02138
David Soane	10 percent owner	C/O SOANE LABS, LLC, 380 NE 72ND TERRACE, MIAMI FL 33138
Robert Patrick Mahoney	officer: Chief Scientific Officer	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Barbara K Finck	director	C/O PROTINE DESIGN LAB, 3858 JACKSON ST, SAN FRANCISCO CA 94118
Kirsten Flowers	director	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
James Sherblom	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Stuart A Randle	director	585 WEST 500 SOUTH, BOUNTIFUL UT 84010
Sullivan Edward Aloysius Jr.	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Sirshendu Roopom Banerjee	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Janice Mccourt	officer: Chief Business Officer	C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Jeffrey S. Hackman	director, officer: See Remarks	12 GILL STREET, SUITE 4650, WOBURN MA 01801
John D. Yee	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Neal Muni	officer: See Remarks	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Phoenix Venture Partners Lp	10 percent owner	36 DOCKSIDE CIRCLE, REDWOOD SHORES CA 94065